The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

The ranibizumab ocular implant (Susvimo) reduces the need for frequent intravitreal anti-VEGF injections in patients with neovascular age-related macular degeneration or diabetic macular edema, and ...

Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema.

Telemedicine helped increase access to endocrinology care for adults with type 2 diabetes and atherosclerotic cardiovascular disease living in rural areas, but several disparities remain ...

A 7-year-old Arabic girl presented to the emergency department with acute vision loss in the left eye that began that morning. SALT LAKE CITY — In this video, Jay Chhablani, MD, professor of ...

46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1First Phase III ...

Zoryve (roflumilast) topical foam, 0.3% Phosphodiesterase type 4 inhibitor Treatment of plaque psoriasis of the scalp and body in adult and pediatric patients aged 12 years and older. Zoryve Foam ...

Approval was based on results from the Phase III ARANOTE trial, in which Nubeqa demonstrated a 46% reduction in the risk of radiographic progression or death when combined with androgen deprivation ...